29 Oct OpGen enters strategic investment agreement with In-Q-Tel
Madison, Wis. – Madison’s OpGen, a provider of in microbial genome analysis, has announced a strategic investment and development agreement with In-Q-Tel, a strategic investment firm that identifies technology solutions for U.S. intelligence community.
The agreement suports the development of OpGen’s new optical mapping systems, which will be used in commercial, academic, and governmental organizations worldwide.
Colin Dykes, OpGen’s chief scientific officer, said in a release that the agreement “dovetails perfectly” with OpGen’s move toward delivering stand-alone instruments and disposables for microbial analysis.
As part of its charter, In-Q-Tel evaluates technology advances with specific applicability to intelligence challenges, including the ability to analyze organisms.
• OpGen’s $23.6M venture capital score could transform hospital care
• OpGen layoffs precede another funding round
• Proceeding with caution at corner of IT & biotech
• OpGen forges agreement with Japanese importer